Diffuse myocardial fibrosis among healthy pediatric heart transplant recipients: Correlation of histology, cardiovascular magnetic resonance, and clinical phenotype

Pediatric Transplantation

Volumn 21, Issue 5, 2017, Pages

  Feingold, Brian ^a   Salgado, Cláudia M ^a   Reyes Múgica, Miguel ^a   Drant, Stacey E ^a   Miller, Susan A ^a   Kennedy, Mark ^b   Kellman, Peter ^c   Schelbert, Erik B ^a,b   Wong, Timothy C ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

allograft survival; cardiac magnetic resonance imaging; chronic rejection; extracellular volume; fibrosis; heart transplantation; interstitium; pediatric

Indexed keywords

AZATHIOPRINE; BRAIN NATRIURETIC PEPTIDE; CYCLOSPORIN; MYCOPHENOLATE MOFETIL; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; EXPLORATORY RESEARCH; EXTRACELLULAR SPACE; FEMALE; GRAFT RECIPIENT; HEART EJECTION FRACTION; HEART HEMODYNAMICS; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HEMATOCRIT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MALE; PHENOTYPE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; BIOPSY; CARDIAC MUSCLE; CARDIOMYOPATHY; CASE CONTROL STUDY; CLINICAL TRIAL; DIAGNOSTIC IMAGING; FIBROSIS; HEART; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSTOPERATIVE COMPLICATION; YOUNG ADULT;

ADOLESCENT; ADULT; BIOPSY; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; EXTRACELLULAR SPACE; FEMALE; FIBROSIS; HEART; HEART TRANSPLANTATION; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; PHENOTYPE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85020077448     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12986     Document Type: Article

References (60)

1. Dipchand AI, Kirk R, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: sixteenth official pediatric heart transplantation report–2013; focus theme: age. J Heart Lung Transplant. 2013;32:979-988.
2. Billingham ME. The postsurgical heart. The pathology of cardiac transplantation. Am J Cardiovasc Pathol. 1988;1:319-334.
3. Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92.
4. Aus Dem Siepen F, Buss SJ, Messroghli D, et al. T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance: quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy. Eur Heart J Cardiovasc Imaging. 2015;16:210-216.
5. Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122:138-144.
6. Fontana M, White SK, Banypersad SM, et al. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson. 2012;14:88.
7. Miller CA, Naish JH, Bishop P, et al. Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging. 2013;6:373-383.
8. White SK, Sado DM, Fontana M, et al. T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging. 2013;6:955-962.
9. Chin CW, Semple S, Malley T, et al. Optimization and comparison of myocardial T1 techniques at 3T in patients with aortic stenosis. Eur Heart J Cardiovasc Imaging. 2014;15:556-565.
10. Kawel N, Nacif M, Zavodni A, et al. T1 mapping of the myocardium: intra-individual assessment of post-contrast T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and Gd-BOPTA. J Cardiovasc Magn Reson. 2012;14:26.
11. Liu S, Han J, Nacif MS, et al. Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials. J Cardiovasc Magn Reson. 2012;14:90.
12. Schelbert EB, Testa SM, Meier CG, et al. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. J Cardiovasc Magn Reson. 2011;13:16.
13. Singh A, Horsfield MA, Bekele S, Khan JN, Greiser A, McCann GP. Myocardial T1 and extracellular volume fraction measurement in asymptomatic patients with aortic stenosis: reproducibility and comparison with age-matched controls. Eur Heart J Cardiovasc Imaging. 2015;16:763-770.
14. Wong TC, Piehler K, Meier CG, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012;126:1206-1216.
15. Wong TC, Piehler KM, Kang IA, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J. 2014;35:657-664.
16. Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2013;32:1147-1162.
17. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24:1710-1720.
18. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson. 2013;15:91.
19. Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med. 2002;47:372-383.
20. Ledesma-Carbayo MJ, Kellman P, Hsu LY, Arai AE, McVeigh ER. Motion corrected free-breathing delayed-enhancement imaging of myocardial infarction using nonrigid registration. J Magn Reson Imaging. 2007;26:184-190.
21. Piehler KM, Wong TC, Puntil KS, et al. Free-breathing, motion-corrected late gadolinium enhancement is robust and extends risk stratification to vulnerable patients. Circ Cardiovasc Imaging. 2013;6:423-432.
22. Messroghli DR, Greiser A, Frohlich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging. 2007;26:1081-1086.
23. Xue H, Shah S, Greiser A, et al. Motion correction for myocardial T1 mapping using image registration with synthetic image estimation. Magn Reson Med. 2012;67:1644-1655.
24. Lee JJ, Liu S, Nacif MS, et al. Myocardial T1 and extracellular volume fraction mapping at 3 tesla. J Cardiovasc Magn Reson. 2011;13:75.
25. Ugander M, Oki AJ, Hsu LY, et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J. 2012;33:1268-1278.
26. Kellman P, Wilson JR, Xue H, et al. Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience. J Cardiovasc Magn Reson. 2012;14:64.
27. Kellman P, Wilson JR, Xue H, Ugander M, Arai AE. Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson. 2012;14:63.
28. Giri S, Chung YC, Merchant A, et al. T2 quantification for improved detection of myocardial edema. J Cardiovasc Magn Reson. 2009;11:56.
29. Rasband WS. ImageJ. Bethesda, MD: National Institutes of Health; 2014.
30. Hadi AM, Mouchaers KT, Schalij I, et al. Rapid quantification of myocardial fibrosis: a new macro-based automated analysis. Cell Oncol (Dordr). 2011;34:343-354.
31. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-381.
32. Heling A, Zimmermann R, Kostin S, et al. Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ Res. 2000;86:846-853.
33. Maisch B. Ventricular remodeling. Cardiology. 1996;87(Suppl 1):2-10.
34. Sun Y, Weber KT. Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones. Ann Med. 1998;30(Suppl 1):3-8.
35. Perens G, Li F, Meier S, Kaur R, Alejos JC, Fishbein M. Clinico-pathologic findings in end-stage pediatric heart transplant grafts. Pediatr Transplant. 2009;13:887-891.
36. Hornick P, Rose M. Chronic rejection in the heart. Methods Mol Biol. 2006;333:131-144.
37. Libby P, Pober JS. Chronic rejection. Immunity. 2001;14:387-397.
38. Mannon RB. Therapeutic targets in the treatment of allograft fibrosis. Am J Transplant. 2006;6:867-875.
39. Booth AJ, Csencsits-Smith K, Wood SC, Lu G, Lipson KE, Bishop DK. Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection. Am J Transplant. 2010;10:220-230.
40. Csencsits K, Wood SC, Lu G, et al. Transforming growth factor beta-induced connective tissue growth factor and chronic allograft rejection. Am J Transplant. 2006;6:959-966.
41. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol. 2005;45:657-687.
42. Ellims AH, Shaw JA, Stub D, et al. Diffuse myocardial fibrosis evaluated by post-contrast t1 mapping correlates with left ventricular stiffness. J Am Coll Cardiol. 2014;63:1112-1118.
43. Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52:1574-1580.
44. Riesenkampff E, Chen CK, Kantor PF, et al. Diffuse myocardial fibrosis in children after heart transplantations: a magnetic resonance T1 mapping study. Transplantation. 2015;99:2656-2662.
45. Ide S, Riesenkampff E, Chiasson DA, et al. Histological validation of cardiovascular magnetic resonance T1 mapping markers of myocardial fibrosis in paediatric heart transplant recipients. J Cardiovasc Magn Reson. 2017;19:10.
46. Verma S, Fedak PWM, Weisel RD, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation. 2002;105:2332-2336.
47. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 2002;105:595-601.
48. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-516.
49. Bull S, White SK, Piechnik SK, et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart. 2013;99:932-937.
50. de Meester de Ravenstein C, Bouzin C, Lazam S, et al. Histological Validation of measurement of diffuse interstitial myocardial fibrosis by myocardial extravascular volume fraction from Modified Look-Locker imaging (MOLLI) T1 mapping at 3 T. J Cardiovasc Magn Reson. 2015;17:48.
51. Iles LM, Ellims AH, Llewellyn H, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging. 2015;16:14-22.
52. Kammerlander AA, Marzluf BA, Zotter-Tufaro C, et al. T1 mapping by CMR imaging: from histological validation to clinical implication. JACC Cardiovasc Imaging. 2016;9:14-23.
53. Lee SP, Lee W, Lee JM, et al. Assessment of diffuse myocardial fibrosis by using MR imaging in asymptomatic patients with aortic stenosis. Radiology. 2015;274:359-369.
54. Mascherbauer J, Marzluf BA, Tufaro C, et al. Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Imaging. 2013;6:1056-1065.
55. Sibley CT, Noureldin RA, Gai N, et al. T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology. 2012;265:724-732.
56. Martinez-Dolz L, Almenar L, Hervas I, et al. Prognostic relationship between two serial determinations of B-type natriuretic peptide and medium-long-term events in heart transplantation. J Heart Lung Transplant. 2008;27:735-740.
57. Martinez-Dolz L, Almenar L, Moro J, et al. Prognostic value of brain natriuretic peptide in heart transplant patients. J Heart Lung Transplant. 2007;26:986-991.
58. Liu CY, Liu YC, Wu C, et al. Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2013;62:1280-1287.
59. Kanal E, Maravilla K, Rowley HA. Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. AJNR Am J Neuroradiol. 2014;35:2215-2226.
60. Feingold B, Zheng J, Law YM, et al. Risk factors for late renal dysfunction after pediatric heart transplantation: a multi-institutional study. Pediatr Transplant. 2011;15:699-705.